xCella Biosciences, Inc.
1490 O'Brien Drive
Suite C
Menlo Park
California
94025
United States
About xCella Biosciences, Inc.
xCella is a protein engineering and drug discovery company based on intellectual property originally developed at Stanford University in the Stanford Photonics Research Center and the laboratory of Dr. Jennifer Cochran in the Stanford Department of Bioengineering. xCella’s proprietary platform enables high throughput screening and engineering of proteins based on functional activity, presenting unprecedented opportunities for the creation of novel therapeutics and other protein-based assets. In addition to its internal drug discovery program, xCella has entered into partnership agreements with leading pharmaceutical and biotechnology companies to develop best in-class protein-based assets in key strategic areas of interest.YEAR FOUNDED:
December 17, 2015
LEADERSHIP:
Founder: Darius Kharabi
3 articles about xCella Biosciences, Inc.
-
Ligand Expands OmniAb® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences
9/10/2020
Ligand Expands OmniAb ® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences The acquired technologies continue to position Ligand’s OmniAb as a best-in-class platform for antibody discovery
-
xCella Announces New Antibody Development Program
4/9/2019
xCella Biosciences announced a new antibody discovery research collaboration with Teva Pharmaceuticals Australia Pty Ltd. xCella will use its xPlorationTM single cell screening platform to identify rare antibodies against an undisclosed target of interest to Teva.
-
Ligand Enters Into Worldwide OmniAb® Platform License Agreement With xCella Biosciences
5/30/2017